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BACKGROUND: Genotype has been implicated in the outcome of ovarian stimulation. The analysis of patient-specific genotypes might
lead to an individualized pharmacogenomic approach to controlled ovarian stimulation (COS). However, the validity of such an approach
remains to be established.
OBJECTIVE AND RATIONALE: To define the impact of specific genotype profiles of follicle-stimulating hormone, luteinizing hormone
and their receptors (FSHR, LHR and LHCGR) on ovarian stimulation outcome. Specifically, our aim was to identify polymorphisms that
could be useful in clinical practice, and those that need further clinical investigation.
SEARCH METHODS: A systematic review followed by a meta-analysis was performed according to the Cochrane Collaboration and
Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines without time restriction. We searched the PubMed/
MEDLINE, Cochrane Library, SCOPUS and EMBASE databases to identify all relevant studies published before January 2017. Only clinical
trials published as full-text articles in peer-reviewed journals were included. The primary outcome was the number of oocytes retrieved.
OUTCOMES: Fifty-seven studies were assessed for eligibility, 33 of which were included in the qualitative and quantitative analyses. Data
were independently extracted using quality indicators. COS outcomes related to seven polymorphisms (FSHR [rs6165], FSHR [rs6166],
FSHR [rs1394205], LHB [rs1800447], LHB [rs1056917], LHCGR [rs2293275] and LHCGR [rs13405728]) were evaluated. More oocytes were
retrieved from FSHR (rs6165) AA homozygotes (five studies, 677 patients, weighted mean difference [WMD]: 1.85, 95% CI: 0.85–2.85, P <
0.001; I2 = 0%) than from GG homozygotes and AG heterozygotes (four studies, 630 patients, WMD: 1.62, 95% CI: 0.28–2.95, P = 0.020;
I2 = 56%). Moreover, stimulation duration was shorter in FSHR (rs6165) AA homozygotes than in AG carriers (three studies, 588 patients,
WMD −0.48, 95% CI: −0.87 to −0.10, P = 0.010, I2 = 44%). A higher number of oocytes (21 studies, 2632 patients WMD: 0.84, 95% CI:
0.19 to 1.49, P = 0.01, I2 = 76%) and metaphase II oocytes (five studies, 608 patients, WMD: 1.03, 95% CI: 0.01–2.05, P = 0.050, I2 = 0%)
was observed in AA than in GG homozygote carriers. FSH consumption was significantly lower in FSHR (rs1394205) GG homozygotes
(three studies, 411 patients, WMD: −1294.61 IU, 95% CI: −593.08 to −1996.14 IU, P = 0.0003, I2 = 99%) and AG heterozygotes (three
studies, 367 patients, WMD: −1014.36 IU, 95% CI: −364.11 to −1664.61 IU, P = 0.002, I2 = 99%) than in AA homozygotes.
WIDER IMPLICATIONS: These results support the clinical relevance of specific genotype profiles on reproductive outcome. Further
studies are required to determine their application in a pharmacogenomic approach to ovarian stimulation.
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Introduction
Ideally, a tailored approach to controlled ovarian stimulation (COS)
in infertile patients would involve a comprehensive evaluation of the
patient’s characteristics, including genotype profile. Pharmacogenom-
ics evaluates how genes influence individual responses to medication.
Pharmacogenomic approaches appeared to be a cost-effective strat-
egy in several medical fields (Patel et al., 2014; Mizzi et al., 2016).
Data regarding the clinical utility of pharmacogenomics in ART are
still scanty (Greb et al., 2005). Nonetheless, increasing evidence indi-
cates that specific genetic characteristics of gonadotrophins and their
receptors could influence the ovarian response to exogenous gona-
dotrophins. Specifically, a common single nucleotide polymorphism
(SNP) of the FSH receptor (FSHR, rs6166) has been associated with
increased FSH consumption during COS (Yao et al., 2011). It has also
been associated with increased basal levels of FSH, which suggests an
impaired response to both endogenous and exogenous gonadotro-
phins (Perez Mayorga et al., 2000; Behre et al., 2005; Simoni and
Casarini, 2014; Alviggi et al., 2016a). Moreover, a FSHR polymorph-
ism at position −29 (FSHR, rs1394205) was found to be associated
with a poor ovarian response (Achrekar et al., 2009b). Similarly, a
suboptimal response to IVF was observed in SNP carriers of the gene
encoding the LH beta subunit (Alviggi et al., 2011, 2013). Recently,
LH receptor SNPs (LHCGR, rs2293275 and LHCGR, rs12470652)
were reported to affect COS and ART (O’brien et al., 2013; Lindgren
et al., 2016; Alviggi et al., 2016b). These findings prompted the
hypothesis that a ‘hypo-response’ to gonadotrophin therapy could be
related to specific genotype characteristics (Alviggi et al., 2016a).
Contrary to poor-responders, ‘hypo-responders’ have a good prog-
nosis for ART in terms of basal characteristics and ovarian reserve,
but require a higher-than-expected dose of gonadotrophins and
more prolonged stimulation to obtain an adequate number of
oocytes (Alviggi et al., 2013).
Given the steady increase in evidence that SNPs affect COS and
ART outcomes, we conducted a systematic review and meta-analysis
data in the attempt to summarize the clinical evidence regarding the
impact of polymorphisms of gonadotrophins and their receptors on
the outcome of COS.
Methods
Protocol and registration
This study was exempt from institutional review board approval because
it did not involve human intervention. We adhered to the Preferred
Reporting Items for Systematic Reviews and Meta-analysis and provide its
checklist in the Supplementary material. The study protocol was regis-
tered at http://www.crd.york.ac.uk/PROSPERO/ (registration number
CRD42016050402) on 31 October 2016, before starting the review
process.
Eligibility criteria
We used the PICO (Patients, Intervention, Comparison and Outcomes)
model to select our study population. We included only women who
underwent COS, and evaluated COS outcomes according to individual
genotype expression (Supplementary Table I).
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Search strategy
We conducted a systematic search using the MEDLINE (PubMed),
EMBASE, SCOPUS and Cochrane Library databases to identify all rele-
vant studies published before January 2017. Combinations of the follow-
ing keywords and MESH search terms were used: ‘COH’, ‘COS’,
‘controlled ovarian stimulation’, ‘ART’, ‘IVF’, ‘ICSI’, ‘FIVET’, ‘IUI’, ‘intra-
uterine insemination’, ‘ovulation induction’, ‘polymorphism’ OR ‘SNP’
‘luteinizing hormone/choriogonadotropin receptor’ ‘LHCGR’, ‘FSH
Receptor’, ‘FSHR’, ‘FSH’, ‘follicle-stimulating hormone’, ‘follicle-stimulat-
ing hormone, beta subunit’, LH’, ‘luteinizing hormone’ and ‘luteinizing
hormone, beta subunit’. No time or language restrictions were adopted,
and queries were limited to human studies. The reference lists of relevant
reviews and articles were also hand-searched.
Selection of studies
Two reviewers (A.C. and D.S.) independently evaluated titles and
abstracts. Duplications were removed using Endnote online software and
manually. Disagreements were resolved by discussion among authors,
and if required, with the involvement of the most experienced authors
(C.A., S.E., C.Y.A, P.H, G.D. and M.S). Only clinical trials published in
peer-reviewed journals were evaluated. Case series, case reports, book
chapters, congress abstracts and gray literature were not included.
Data extraction
Data were extracted independently by two reviewers (A.C. and D.S.)
using predefined data fields, and study quality indicators. Discrepancies
were resolved by discussion with the senior authors (C.A., S.E., C.Y.A.,
P.H, G.D. and M.S.).
Risk of bias, summary measures and
synthesis of the results
The risk of bias and the quality of the studies included in this meta-analysis
were evaluated. Two authors (A.C. and D.S.) independently assessed the
risk bias of each study. The senior authors (C.A., S.E., C.Y.A., P.H., G.D.
and M.S.) resolved conflicts. The Newcastle–Ottawa scale (NOS) score
was used to evaluate the studies included, and judgment on each one
was passed according to three issues: selection of the study group, com-
parability between groups and ascertainment of exposed/not exposed
cohorts (Wells et al., 2004).
The primary outcome was the number of oocytes retrieved.
Secondary outcomes were: FSH consumption, stimulation duration (num-
ber of days of gonadotrophin use for COS), the number of metaphase II
(MII) oocytes and ongoing pregnancy rate (OPR). OPR was defined as a
pregnancy diagnosed by ultrasonographic visualization of at least one ges-
tational sac. Bias across studies regarding the primary outcome was
assessed using visual inspection of funnel plots, the trim and fill method
(Duval, 2006) and the Egger test (Egger et al., 1997).
Quantitative analysis
Statistical analysis was carried out using Review Manager 5.3 (The Nordic
Cochrane Centre, The Cochrane Collaboration). Categorical data were
combined with a pooled odds ratio (OR) using the Mantel–Haenszel
method. Continuous data were combined with weighted mean difference
(WMD) using the inverse variance method. When at least three studies
were available, a meta-analysis was conducted using the fixed-effect mod-
el. The random-effect model was used in case of significant heterogeneity
among studies. Heterogeneity was assessed using the percentage of total
variation in the estimated effect across studies (I2). An I2 value > 50%
indicates substantial heterogeneity. P-values <0.05 were considered stat-
istically significant. We applied Bonferroni correction in case of statistical
significance. Subgroup analysis by type of exogenous FSH (i.e. recombin-
ant versus urinary) was conducted to assess potential sources of hetero-
geneity in the number of oocytes retrieved. We also evaluated
differences in FSH basal level in relation to FSHR 919 G>A (rs6165) and
FSHR 2039 G>A (rs6166) genotype distribution. Sensitivity analysis was
carried out to assess the leverage of studies with a low risk of bias (NOS ≥ 6)
on the results. For the primary outcome, an additive effect of genotypes
was also tested. Using the R statistical package (R Foundation for
Statistical Computing, Vienna, Austria), we estimated Hedges’ g and the
corresponding SE for each study adopting a simulation approach based
on a linear regression model (John et al., 2018). In detail, to test the addi-
tive model pooled Hedges’ g was computed with a fixed-effect model or
random-effect model in case of significant heterogeneity among studies.
Results
Study selection and study characteristics
A total of 1051 items were identified (Fig. 1). After removing 167
duplicates using Endnote software (EndNote X 6.0.1, Thomson
Reuters, USA, California State University) and 45 duplicates manually,
the titles and abstracts of 839 paper were scrutinized. The reference
lists of relevant reviews were hand-searched. Fifty-nine articles were
assessed for eligibility. Fifteen articles were excluded because they
did not fulfill the inclusion criteria. Data extraction was not possible
in the case of 10 articles (Daelemans et al., 2004; De Castro et al.,
2004; D’alva et al., 2005; Livshyts et al., 2009; Lazaros et al., 2012;
Boudjenah et al., 2014; Colognato et al., 2014; Almawi et al., 2015;
Laisk-Podar et al., 2015; Valkenburg et al., 2015), because COS and
ART were not evaluated in relation to polymorphism genotype
expression. Data duplication was detected in studies by Desai et al.
(2011, 2013) and by Mohiyiddeen and collaborators (Mohiyiddeen
et al., 2013a; 2013b). Of these, we included two studies in our ana-
lysis (Desai et al., 2011; Mohiyiddeen et al., 2013b). We extracted
data regarding MII oocytes from the Mohiyiddeen et al. (2013a) study
that were not reported in their subsequent paper (Mohiyiddeen
et al., 2013b). Thirty-three studies were included in our quantitative
and qualitative analysis (Fig. 1 and Table I). Seven polymorphisms
were reported in these studies: FSHR 919 G>A (rs 6165), FSHR
2039 G>A (rs6166), FSHR −29 G>A (rs1394205), LHB 82 T>C
(rs1800447), LHB 1502 G>A (rs1056917), LHCGR 935 A>G
(rs2293275) and LHCGR 3442–25 260 A>G (rs13405728).
Risk of bias within studies
Bias assessment within studies is shown in Table I. A high rate of
agreement, evaluated by k-Cohen calculation, was observed between
the two authors (A.C. and D.S.; k-Cohen = 0.83).
Summary of results
The results of the quantitative analysis of each outcome measure
according to genotype distribution are reported below and summar-
ized in Table II.







upd/article/24/5/599/5039912 by guest on 26 O
ctober 2020
FSH consumption
A meta-analytic approach was possible only for FSHR (rs6165), FSHR
(rs6166) and FSHR (rs1394205). No data were found regarding LHB
(rs1056917).
Four studies (Laven et al., 2003; Achrekar et al., 2009a; Genro
et al., 2012; Yan et al., 2013), for a total of 729 women, evaluated
FSH consumption in relation to the FSHR (rs6165) genotype distribu-
tion. FSH consumption did not differ statistically among FSHR
(rs6165) AA homozygotes, GG homozygotes (Random WMD:
227.64 IU, 95% CI: −452.95 to 908.22 IU, I2 = 96%), and AG het-
erozygotes (Random WMD: 110.24 IU, 95% CI: −323.57 to 544.05
IU, I2 = 93%). Similarly, FSH consumption did not differ between GG
homozygotes and AG heterozygotes (Random WMD: 134.09 IU,
95% CI: −162.06 to 430.25, I2 = 81%) (Supplementary Fig. S1).
Eighteen studies (Perez Mayorga et al., 2000; Sudo et al., 2002;
Laven et al., 2003; Behre et al., 2005; Jun et al., 2006; Loutradis et al.,
2006; Achrekar et al., 2009a; Huang et al., 2010, 2015; Nordhoff
et al., 2011; Sheikhha et al., 2011; Anagnostou et al., 2012; Genro
et al., 2012; Lledo et al., 2013; Yan et al., 2013; Mohiyiddeen et al.,
2013b; Lindgren et al., 2016; Lledó et al., 2016), for a total of 4 094
women, evaluated FSH consumption according to FSHR (rs6166)
genotype distribution. FSH consumption in FSHR AA homozygotes
was comparable to that in GG homozygotes (Random WMD:
−158.50 IU, 95% CI: −338.32 to 21.32 IU, I2 = 96%) and AG het-
erozygotes (Random WMD: 18.00 IU, 95% CI: −119.36 to 155.35
IU, I2 = 96%). Similarly, no differences were found between FSHR
GG homozygotes and AG heterozygotes (Random WMD: −137.53
IU, 95% CI: −293.04 to 17.97 IU, I2 = 86%) (Supplementary Fig. S2).
Three studies (Achrekar et al., 2009b; Desai et al., 2011; Tohlob
et al., 2016), for a total of 709 women, evaluated FSH consumption
according to the FSHR (rs1394205) genotype. The consumption of
FSH was significantly lower in FSHR GG homozygotes than in FSHR
AA homozygotes (Random WMD: −1294.61 IU, 95% CI: −1996.14
to −593.08, P < 0.001, Bonferroni adjusted P = 0.008, I2 = 99%),
whereas no differences were observed between GG and AG hetero-
zygotes (Random WMD: −277.84 IU, 95% CI: −1145.28 IU to
589.60, I2 = 100%). FSH consumption was lower in AG heterozy-
gotes than in FSHR AA homozygotes (Random WMD: −1014.36 IU,
95% CI: −1664.61 to −364.11, P = 0.002, Bonferroni adjusted P =
0.006, I2 = 99%) (Fig. 2).
Two studies (Alviggi et al., 2011; Alviggi et al., 2013) reported FSH
consumption according to LHB (rs1800447) genotype distribution.
Both reported a significantly higher FSH consumption in variant car-
riers compared with wild-type carriers.
Figure 1 Study flow chart.
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One study (Lindgren et al., 2016) reported FSH consumption in
relation to the distribution of the LHCGR (rs2293275) genotype. No
significant differences among genotypes were detected.
One study (Yin et al., 2015) reported FSH consumption in relation
to the distribution of the LHCGR (rs13405728) genotype. No signifi-
cant differences among genotypes were reported.
The overall effect estimated by the analyses indicated that FSH con-
sumption was only affected by the presence of FSHR (rs1394205).
However, these results may be conservative given the high hetero-
geneity among trials and the relatively small number of patients
evaluated.
Stimulation duration
A meta-analytic approach regarding stimulation duration was possible
only for FSHR (rs6165) and FSHR (rs6166). No data on the other
polymorphisms were found.
Three studies (Laven et al., 2003; Genro et al., 2012; Yan et al.,
2013) for a total of 679 patients, evaluated stimulation duration in
relation to the distribution of the FSHR (rs6165) genotype. The dur-
ation of stimulation did not differ between FSHR AA homozygotes
and GG homozygotes (Random WMD: −0.59, 95% CI: −1.24 to
0.05, I2 = 60%), however it was significantly shorter in AA than in
AG heterozygotes (Fixed WMD: −0.48, 95% CI: −0.87 to −0.10,
.............................................................................................................................................................................................
Table I Characteristics and Newcastle–Ottawa scale score of studies included in a systematic review and meta-analysis
of the impact of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation.
References SNPs evaluated Country Number of
patients




Achrekar et al. (2009a) FSHR (rs6165), FSHR (rs6166) India 50 30.09 ± 1.50 Retrospective 7
Achrekar et al. (2009b) FSHR (rs1394205) India 150 NA Retrospective 7
Alviggi et al. (2009) LHB (rs1800447) Italy 60 30.81 ± 3.39 Retrospective 6
Alviggi et al. (2013) LHB (rs1800447) Denmark 220 30.65 ± 3.95 Retrospective 6
Alviggi et al., 2016a FSHR (rs6166) Italy 42 30.57 ± 4.37 Retrospective 6
Anagnostou et al. (2012) FSHR (rs6166) Greece 109 35.00 ± 4.50 Prospective 6
Behre et al. (2005) FSHR (rs6166) Germany 93 33.10 ± 0.64 Prospective 7
Dan et al. (2015) FSHR (rs1394205) China 158 NA Prospective 7
Davar et al. (2014) LHB (rs1056917) Iran 220 29.94 ± 5.98 Prospective 7
De Castro et al. (2003) FSHR (rs6166) Spain 102 33.70 ± 3.10 Retrospective 6
Desai et al. (2011) FSHR (rs1394205) India 100 33.11 ± 0.82 Retrospective 8
Genro et al. (2012) FSHR (rs6165), FSHR (rs6166) Brazil 124 34.95 ± 3.82 Prospective 8
Huang et al. (2015) FSHR (rs6166) China 1250 31.31 ± 3.34 Retrospective 6
Huang et al. (2010) FSHR (rs6166) China 136 30.33 ± 3.31 Prospective 6
Jun et al. (2006) FSHR (rs6166) South Corea 263 32.60 ± 0.40 Prospective 7
Klinkert et al. (2006) FSHR (rs6166) The Netherlands 105 36.90 ± 5.10 Prospective 6
Laven et al. (2003) FSHR (rs6165), FSHR (rs6166) Holland 148 28.20 ± 3.10 Prospective 6
Lazaros et al. (2013) FSHR (rs6165), FSHR (rs6166) Greece 604 NA Retrospective 6
Lindgren et al. (2016) LHCGR (rs2293275), FSHR (rs6166) Denmark 384 31.92 ± 2.90 Prospective 8
Lledo et al. (2013) FSHR (rs6166) Spain 145 25.60 ± 3.80 Retrospective 6
Lledo et al. (2016) FSHR (rs6166) Spain 191 25.60 ± 3.90 Retrospective 6
Loutradis et al. (2006) FSHR (rs6166) Greece 125 30.30 ± 3.00 Retrospective 5
Mohiyiddeen et al. (2013a) FSHR (rs6166) UK 212 33.17 ± 3.50 Prospective 7
Mohiyiddeen et al. (2013b) FSHR (rs6166) UK 504 33.50 ± 3.70 Prospective 7
Nordhoff et al. (2011) FSHR (rs6166) Germany 22 32.40 ± 3.35 Retrospective 3
Perez Mayorga et al. (2000) FSHR (rs6166) Germany 161 32.60 ± 0.50 Prospective 6
Yin et al. (2015) LHCGR (rs13405728) China 236 NA Prospective 6
Sheikhha et al. (2011) FSHR (rs6166) Iran 108 29.63 ± 4.70 Retrospective 6
Sudo et al. (2002) FSHR (rs6166) Japan 522 31.83 ± 0.77 Retrospective 5
Tohlob et al. (2016) FSHR (rs1394205) UK 559 33.23 ± 5.1 Retrospective 6
Trevisan et al. (2014) FSHR (rs6165), FSHR (rs6166) Italy 149 NA Retrospective 5
Yan et al. (2013) FSHR (rs6165), FSHR (rs6166) China 450 32.15 ± 4.96 Retrospective 6
Zalewski et al. (2013) FSHR (rs6166) Poland 22 33.10 ± 5.00 Retrospective 3
NOS, Newcastle–Ottawa scale; FSHR, FSH receptor; LHCGR, LHCG receptor; SNP, single nucleotide polymorphism; SD, standard deviation; NA, not available.







upd/article/24/5/599/5039912 by guest on 26 O
ctober 2020
P = 0.01, Bonferroni adjusted P = 0.04, I2 = 44%). On the contrary,
stimulation duration did not differ between FSHR GG homozygotes
and AG heterozygotes (Fixed WMD −0.29, 95% CI: −0.95 to 0.37,
I2 = 0%) (Fig. 3).
Fifteen studies (De Castro et al., 2003; Laven et al., 2003; Behre
et al., 2005; Klinkert et al., 2006; Loutradis et al., 2006; Huang et al.,
2010; Nordhoff et al., 2011; Genro et al., 2012; Lledo et al., 2013;
Yan et al., 2013; Zalewski et al., 2013; Huang et al., 2015; Alviggi
et al., 2016a) for a total of 3 069 women, evaluated stimulation dur-
ation in relation to the distribution of the FSHR (rs6166) genotype.
The duration of stimulation did not differ among FSHR AA homozy-
gotes, GG homozygotes (Fixed WMD: −0.01, 95% CI: −0.16 to 0.14
days, I2 = 17%) and AG heterozygotes (Fixed WMD: 0.01, 95% CI:
−0.04 to 0.05, I2 = 27%). Lastly, no differences were observed between
FSHR GG homozygotes and FSHR AG heterozygotes (Fixed WMD:
−0.12, 95% CI: −0.29 to 0.04, I2 = 2%) (Supplementary Fig. S3).
.............................................................................................................................................................................................
Table II Pooled effect estimates including only FSH receptor haplotypes with significant overall effect on ovarian
stimulation outcomes.
FSHR variant Comparison Parameter Effect size [95% CI] I2% Test for overall effect (P-value)
FSHR (rs6165) AA versus GG Stimulation duration −0.59 [−1.24, 0.05] 60 NS
Number of oocytes 1.85 [0.85, 2.85] 0 0.008*
AA versus AG Stimulation duration −0.48 [−0.87, −0.10] 44 0.04*
Number of oocytes 1.62 [0.28, 2.95] 56 0.052*
AG versus GG Stimulation duration −0.29 [−0.95, 0.37] 0 NS
Number of oocytes −0.37 [−1.51, 0.78] 18 NS
FSHR (rs6166) AA versus GG Number of oocytes 0.84 [0.19, 1.49] 76 0.03*
Number of MII oocytes 1.03 [0.01, 2.05] 0 NS
AA versus AG Number of oocytes 0.18 [−0.84, 0.48] 85 NS
Number of MII oocytes 0.79 [−0.05, 1.62] 0 NS
AG versus GG Number of oocytes 0.88 [0.12, 1.63] 76 0.04*
Number of MII oocytes 0.34 [−0.57, 1.26] 49 NS
FSHR (rs1394205) GG versus AA FSH consumption −1294.61 [−1996.14,−593.08] 99 0.008*
AA versus AG FSH consumption −1014.36 [−1664.61,−364.11] 99 0.006*
AG versus GG FSH consumption −277.84 [−1145.28, 589.60] 100 NS
NS, not significant; *Bonferroni adjusted P-value.
Figure 2 Forest plots of differences among FSHR (rs1394205) genotype carriers in relation to FSH consumption. (A) (rs1394205) G homozygotes
versus A homozygotes. (B) (rs1394205) heterozygotes versus A homozygotes. (C) (rs1394205) G homozygous versus heterozygous.
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In summary, the only difference observed was a shorter duration of
stimulation in FSHR (rs6165) AA homozygotes than in AG heterozygotes.
Number of oocytes retrieved
A meta-analytic approach was possible only for FSHR (rs6165), FSHR
(rs6166) and FSHR (rs1394205). No data were found regarding
LHCGR (rs2293275).
Five studies (Achrekar et al., 2009a; Genro et al., 2012; Lazaros
et al., 2013; Yan et al., 2013; Trevisan et al., 2014), for a total of
1020 women, reported the number of oocytes retrieved in relation
to the distribution of the FSHR (rs6165) genotype. The number of
oocytes retrieved was significantly higher in AA homozygotes than in
either GG homozygotes (Fixed WMD: 1.85, 95% CI: 0.85–2.85, P <
0.001, Bonferroni adjusted P = 0.008, I2 = 0%). No difference was
detected among AG heterozygotes, GG homozygotes (Fixed WMD:
−0.37, 95% CI: −1.51 to 0.78, I2 = 18%) and AA homozygotes
(Random WMD: 1.62, 95% CI: 0.28–2.95, P = 0.02, Bonferroni
adjusted P = 0.052, I2 = 56%) (Fig. 4). The additive model was mar-
ginally significant in the association between FSHR (rs6165) and num-
ber of oocytes retrieved (pooled Hedges’ g −0.129; Fixed: 95% CI
−0.258 to 0.000, P = 0.05, I2 = 43%).
Twenty-one studies (Perez Mayorga et al., 2000; Sudo et al., 2002;
De Castro et al., 2003; Behre et al., 2005; Jun et al., 2006; Klinkert
et al., 2006; Loutradis et al., 2006; Achrekar et al., 2009a; Huang
et al., 2010, 2015; Nordhoff et al., 2011; Sheikhha et al., 2011; Genro
et al., 2012; Lazaros et al., 2013; Lledo et al., 2013, 2016; Yan et al.,
2013; Zalewski et al., 2013; Mohiyiddeen et al., 2013b; Trevisan
et al., 2014; Alviggi et al., 2016a) including 4 425 women, reported
the number of oocytes retrieved in relation to the distribution of the
FSHR (rs6166) genotype. The number of oocytes retrieved was sig-
nificantly higher in AA homozygotes than in GG homozygotes
(Random WMD: 0.84, 95% CI: 0.19–1.49, P = 0.01, Bonferroni
adjusted P = 0.03, I2 = 76%), but it was similar to that retrieved from
AG heterozygotes (Random WMD: −0.18, 95% CI: −0.84 to 0.48,
I2 = 85%). The number of oocytes was significantly higher in AG het-
erozygotes than in GG homozygotes (Random WMD: 0.88, 95% CI:
0.12–1.63, P = 0.02, Bonferroni adjusted P = 0.04, I2 = 76%) (Fig. 5).
The additive model was not significant for the association between
FSHR (rs6165) and number of oocytes retrieved (pooled Hedges’ g
−0.072 95% CI −0.179 to 0.035, P = 0.19, I2 = 65%).
Three studies (Achrekar et al., 2009b; Desai et al., 2011; Tohlob
et al., 2016), including 709 women, evaluated the number of oocytes
retrieved in relation to the distribution of the FSHR (rs1394205)
genotype. The number of oocytes retrieved was lower, albeit not sig-
nificantly lower, in FSHR (rs1394205) AA homozygotes than in either
GG homozygotes (Random WMD: −5.20, 95% CI: −11.22 to 0.82,
I2 = 99%) or AG heterozygotes (Random WMD: −3.88, 95% CI:
−7.93 to 0.18, I2 = 98%). No differences were observed between
GG homozygotes and AG heterozygotes (Random WMD: −1.29,
95% CI: −3.51 to 0.93, I2 = 97%) (Supplementary Fig. S4).
Two studies (Alviggi et al., 2011; Alviggi et al., 2013) reported the
number of oocytes retrieved in relation to the distribution of the LHB
(rs1800447) genotype. In both studies, the number of oocytes
retrieved did not differ among genotypes.
Figure 3 Forest plots of differences among FSHR (rs6165) genotype carriers in relation to stimulation duration. (A) (rs6165) A homozygotes ver-
sus G homozygotes. (B) (rs6165) A homozygotes versus heterozygotes. (C) (rs6165) heterozygous versus G homozygotes.
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Only one study (Davar et al., 2014) reported the number of
oocytes retrieved in relation to the LHB (rs1056917) genotype, and
no significant differences among genotypes were observed.
Similarly, only one study (Yin et al., 2015) reported the number of
oocytes retrieved in relation to the distribution of the LHCGR
(rs13405728) genotype, and there were no significant differences
among genotypes.
The overall effect size indicates that the FSHR (rs6165) and FSHR
(rs6166) genotypes impacted on the number of oocytes retrieved. In
both cases, AA homozygosity was associated with a higher number
of oocytes retrieved, whereas GG homozygotes exerted an opposite
effect. The effect size estimated for the FSHR (rs6166) genotype may
be conservative because of the high heterogeneity.
Number of MII oocytes
A meta-analytic approach was possible only in the case of FSHR
(rs6166). No data were found regarding LHB (rs1056917).
Only two studies (Genro et al., 2012; Trevisan et al., 2014) evalu-
ated the number of MII oocytes retrieved in relation to FSHR
(rs6165). In both studies, the number of MII oocytes did not differ
among genotypes.
Five studies (Genro et al., 2012; Mohiyiddeen et al., 2013a;
Trevisan et al., 2014; Lindgren et al., 2016; Lledó et al., 2016) includ-
ing 1185 patients, reported the number of MII oocytes retrieved in
relation to the distribution of the FSHR (rs6166) genotype. The num-
ber of MII oocytes was higher in AA homozygotes than in GG homozy-
gotes but the differences did not reach statistical significance after
Bonferroni correction (Fixed WMD: 1.03, 95% CI: 0.01–2.05, P = 0.05,
Bonferroni adjusted P = 0.14, I2 = 0%). No significant differences were
observed between AA homozygotes and AG heterozygotes (Fixed
WMD: 0.79, 95% CI: −0.05 to 1.62, I2 = 0%), or between GG
homozygotes and AG heterozygotes (Fixed WMD: 0.34, 95% CI:
−0.57 to 1.26, I2 = 49%) (Supplementary Fig. S5).
Only two studies (Desai et al., 2011; Dan et al., 2015) reported
the number of MII oocytes in relation to the distribution of the FSHR
(rs1394205) genotype. In detail, Dan et al. (2015) observed a signifi-
cantly higher number of MII oocytes in GG carriers than in AG/AA
carriers. Similarly, Desai et al. (2011) found a significantly higher num-
ber of MII oocytes in GG carriers than in AG and AA carriers.
The only study to report the number of MII oocytes retrieved in
relation to the LHB (rs1800447) genotype did not find any difference
between wild-type and variant carriers (Alviggi et al., 2013). Similarly,
the only study to report the number of MII oocytes retrieved in
Figure 4 Forest plots of differences among FSHR (rs6165) genotype carriers in relation to the number of oocytes retrieved. (A) (rs6165) A
homozygotes versus G homozygotes. (B) (rs6165) A homozygotes versus heterozygotes. (C) (rs6165) heterozygous versus G homozygotes.
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Figure 5 Forest plots of differences among FSHR (rs6166) genotype carriers in relation to the number of oocytes retrieved. (A) (rs6166)
A homozygotes versus G homozygotes. (B) (rs6166) A homozygotes versus heterozygotes. (C) (rs6166) heterozygotes versus G homozygotes.
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relation to the LHCGR (rs2293275) genotype did not find any differ-
ence among the haplotypes identified (Lindgren et al., 2016). The
only study to report the number of MII oocytes retrieved in relation
to the distribution of the LHCGR (rs13405728) genotype did not find
any differences among genotypes (Yin et al., 2015).
The overall effect size indicates that the FSHR (rs6166) genotype
did not significantly affect the number of mature oocytes retrieved.
However, given the limited number of studies available, these obser-
vations should be viewed with caution.
OPR
A meta-analytic approach to OPR was possible only for FSHR
(rs6166). No data were found regarding the FSHR (rs6165), LHB
(rs1056917) or LHCGR (rs13405728) genotypes.
Seven studies (Jun et al., 2006; Sheikhha et al., 2011; Lledo et al.,
2013; Mohiyiddeen et al., 2013b; Huang et al., 2015; Lindgren et al.,
2016; Alviggi et al., 2016a) including 3191 patients, evaluated OPR in
relation to the distribution of the FSHR (rs6166) genotype. The over-
all OR did not differ among AA homozygotes, GG homozygotes
(Fixed OR: 0.89, 95% CI: 0.70–1.12, I2 = 0%) and AG heterozygotes
(Fixed OR: 0.97, 95% CI: 0.82–1.16, I2 = 29%). Moreover, no signifi-
cant differences were observed between GG homozygotes and AG
heterozygotes (Fixed OR: 0.95, 95% CI: 0.77–1.18, I2 = 0%)
(Supplementary Fig. S6).
Only two studies (Achrekar et al., 2009b; Tohlob et al., 2016)
reported OPR in relation to FSHR (rs1394205). Achrekar et al.
(2009b) reported a comparable OPR among GG, AG and AA car-
riers, whereas Tohlob et al. (2016) reported a higher OPR in women
carrying the A allele than in those carrying the G allele (crude OR
1.32, 95% CI 1.01–1.74, P = 0.04), but this association was not sig-
nificant when adjusted for the number of embryos transferred.
The only study to report OPR in relation to LHB (rs1800447) did
not find any difference between wild-type and variant carriers (Alviggi
et al., 2013).
Only one study (Lindgren et al., 2016) reported OPR in relation to
LHCGR (rs2293275). Differences in terms of OPR were observed
among haplotypes (AA: 18%; AG: 27%; GG: 31%, P = 0.037), with a
higher prevalence in GG carriers.
Risk of bias across studies
The risk of significant bias across studies regarding the primary out-
come was rejected by Egger’s test (P = 0.828 for FSHR rs6166; P =
0.27 for FSHR rs6165, and P = 0.12 for FSHR rs1394205), visual
inspection of the funnel plots, and the trim and fill method
(Supplementary Fig. S7).
Subgroup and sensitivity analyses
We estimated the number of oocytes retrieved according to type of
gonadotrophin, namely recombinant versus urinary FSH (Fig. 6). We
did not include papers in which both gonadotrophins were used for
COS (Behre et al., 2005; Jun et al., 2006; Huang et al., 2010;
Sheikhha et al., 2011; Mohiyiddeen et al., 2013b) or in which the for-
mulation adopted was not clearly stated (Achrekar et al., 2009a).
While a higher number of oocytes were retrieved in AA FSHR
(rs6166) carriers than in GG carriers when recombinant FSH was
used (Fixed WMD 1.15, 95% CI 0.53-1.76, P = 0.0003, Bonferroni
Figure 6 Forest plots of differences between FSHR (rs6166) AA versus GG carriers considering the number of oocytes retrieved oocytes
retrieved. (A) recombinant gonadotropin (B) urinary gonadotropin.
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adjusted 0.0009, I2 = 43%) no differences were observed when urin-
ary gonadotrophin was used (Random WMD 0.68, 95% CI: −2.19 to
3.54; I2 = 86%). Concerning the FSHR (rs6165) genotype, FSH basal
levels did not differ among haplotypes after Bonferroni correction
(Supplementary Fig. S8). On the other hand, FSH basal levels were
significantly lower in AA than in GG FSHR (rs6166) carriers (Fixed
WMD −0.54, 95% CI −0.72 −0.36, P < 0.00001, Bonferroni
adjusted P < 0.0001, I2 = 21%) (Fig. 7).
Lastly, sensitivity analysis revealed that the pooled effect sizes were
affected only with regard to the number of retrieved oocytes




We conducted this systematic review in the attempt to unravel the
role of gene polymorphisms of gonadotrophins and their receptors
on the outcome of COS. We evaluated OPR rather than live birth
rate because the many features that can affect the later stages of
pregnancy may confound the impact of folliculogenesis-related poly-
morphisms. Our findings indicate that FSHR polymorphisms affect
the outcome of COS. In particular, FSH consumption was higher in A
allele homozygous carriers of the FSHR (rs1394205) genotype.
Furthermore, the number of oocytes retrieved was significantly higher
in FSHR (rs6165) AA carriers, and ovarian stimulation was significantly
shorter in these patients than in GG and AG carriers. Similarly, the
number of oocytes retrieved was significantly higher in FSHR (rs6166)
AA carriers than in GG carriers. Although neither polymorphism had
an additive effect, a significant impact on the number of oocytes was
observed under co-dominance (AA versus GG and AG versus GG)
for FSHR rs6166 and only under homozygote models (AA versus
GG) for FSHR rs6165. Therefore, both FSHR polymorphisms seem to
influence responsiveness to COS treatment.
Gonadotrophin type seems to affect the number of oocytes
retrieved in relation to FSHR (rs6166) genotype distribution. In fact,
the number of oocytes retrieved was significantly higher in AA car-
riers than in GG carriers when recombinant FSH was used but not
when urinary FSH was used. FSHR (rs6166) also affects endogenous
levels of FSH as shown by the finding of higher plasma FSH values in
GG carriers than in AA carriers. Lastly, the FSHR (rs6166) genotype
did not significantly affect OPR.
The results of our review of gonadotrophins and their receptor
polymorphisms conducted with a quantitative approach are consist-
ent with those reported in qualitative reviews (Altmae et al., 2011).
However, it remains to be determined whether a pharmacogenomic
approach could counteract the effect of such polymorphisms. Behre
et al. (2005) partially addressed this issue by stratifying normogona-
dotrophic patients according to the distribution of the FSHR (rs6166)
genotype, and found that increasing daily FSH dose from 150 to
225 IU/day counteracted the lower estradiol levels in GG carriers.
Given the paucity of data, we were unable to carry out a meta-
analysis of remnant gonadotrophins and their receptor polymorphisms
[LHB (rs1800447), LHB 1502 G>A (rs1056917), LHCGR 935 A>G
(rs2293275) and LHCGR 3442–25 260 A>G (rs13405728)].
In summary, our meta-analysis demonstrates that specific poly-
morphisms of gonadotrophins and their receptors modulate the
ovarian response to exogenous FSH. On the other hand, further
studies are required to evaluate the impact of these polymorphisms
on OPR and live birth rate. In this context, it is noteworthy that ART
births are greatly influenced by various factors, most of which occur
during the late stages of pregnancy and transcend the ‘physiological’
effects of gonadotrophins and their receptors. In other words, we
maintain that the ovarian response is more reliable than pregnancy
rate in determining the effect of gonadotrophins and their receptor
polymorphisms on COS.
Interpretation of results and clinical
considerations
Our findings can be related to the molecular characteristics of the
genotypes associated with the response to COS (Table III). The FSHR
gene carries more than 2000 SNPs, although only FSHR (rs6165) and
FSHR (rs6166) seem to play a prominent role in the response to
COS. Both SNPs cause an amino acid exchange: in FSHR (rs6166),
asparagine is substituted by serine thereby introducing a potential
phosphorylation site, whereas in FSHR (rs6165) threonine is substi-
tuted by alanine, which results in a change from a polar to a nonpolar
hydrophobic amino acid thereby removing a potential O-linked glyco-
sylation site. These genotypes are in nearly complete linkage disequi-
librium, except in some African populations (Simoni and Casarini,
2014; Casarini et al., 2015). In vitro studies conducted using human
granulosa cells showed that GG carriers of the FSHR (rs6166) geno-
type have greater resistance to FSH than do AA carriers (Casarini
et al., 2014, 2015). Our findings corroborate these previous observa-
tions. Indeed, we found that GG FSHR (rs6166) carriers had higher
ovarian resistance to exogenous gonadotrophin and consequently had
fewer oocytes compared with AA carriers. Moreover, we demon-
strate that such FSHR resistance involves also endogenous FSH levels,
as reported elsewhere (Fig. 7) (Mohiyiddeen and Nardo, 2010).
These effects corroborate the potential impaired function of FSHR in
G allele carriers and could explain why GG allele carriers have an
impaired prognosis to COS as fewer oocytes are collected in these
patients. FSHR function is controlled in both men and women by
another FSH beta subunit (rs10835638) polymorphism (Grigorova
et al., 2010; Ferlin et al., 2011; La Marca et al., 2013), which is signifi-
cantly correlated with FSH beta subunit transcriptional activity and
metabolism (Hoogendoorn et al., 2003). There is also evidence that
FSHR (rs6166) could interact with polymorphisms that influence ART
outcomes. Indeed, in a large cohort study, FSHR (rs6166) and LHCGR
(rs2293275) allele G carriers had a 4-fold increased chance of preg-
nancy versus A carriers of both polymorphisms. Moreover, the num-
ber of mature oocytes was significantly higher in subjects with FSHR
(rs1394205) GG plus FSHR (rs6166) AA genotypes than in other
genotype combinations of these polymorphisms (Desai et al., 2013).
The finding of Borgbo et al. (2015) that FSHR (rs6166) and FSHR
(rs6165) GG carriers had higher LHCGR gene expression but lower
anti-Müllerian hormone (AMH) receptor-2 expression versus carriers
of other haplotypes suggested that these polymorphisms could affect
the protein expression of human antral follicles. Nonetheless, it
remains to be established whether FSHR (rs6166) and FSHR (rs6165)
affect FSHR protein expression.
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Figure 7 Forest plots of differences among FSHR (rs6166) genotype carriers considering FSH basal levels. (A) (rs6166) A homozygotes versus G
homozygotes. (B) (rs6166) A homozygotes versus heterozygotes (C) (rs6166) heterozygotes versus G homozygotes.
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Table III Worldwide distribution, pathogenic mechanism and clinical effects of SNPs significantly related to COS outcome.
Gene refSNP Chromosome DNA
nucleotide
Ancestral allele Amino acid
and allele
Worldwide distribution Protein Pathogenic
mechanism
Clinical effect
FSHR rs6166 2 c.919 G>A G A = Asn = N G allele is highly prevalent in
North-Western Pakistan,
Siberia, Mato Grosso, (Brazil)
and Oceania (Simoni and
Casarini, 2014)
N680S Greater in vivo resistance
to FSH activity Casarini
et al. (2014)
Higher FSH basal levels in G carriers Perez Mayorga et al. (2000);
Huang et al. (2015)
Highest amount of FSH required during COS in G carriers
G = Ser = S
FSHR rs6165 2 c.2039 G>A A A = Thr = T G allele shows a similar
distribution of rs6166 with
exception of African
population (African ancestry
in Southwest USA, Kenya,
Nigeria) (Simoni and
Casarini, 2014)
T307A Greater in vivo resistance
to FSH activity Simoni and
Casarini (2014)
Higher FSH basal levels Yan et al. (2013)
Highest amount of FSH required during COS in T carriers
Achrekar et al. (2009a)
G = Ala = A





/ A allele showed reduced
transcriptional activity
compared with G allele
(Nakayama et al., 2006)
Higher amount of FSH required during COS In allele A carriers
Achrekar et al. (2009b)




W8R Shorter half-life than wild-
type form (Haavisto et al.,
1995)
Higher amount of exogenous FSH required during COS
Alviggi et al. (2011); Alviggi et al. (2013)C = Arg = R








pathway Lindgren et al.
(2016)
Higher ongoing pregnancy rate in SS carriers
Lindgren et al. (2016)G = Ser = S















upd/article/24/5/599/5039912 by guest on 26 O
ctober 2020
Despite the linkage disequilibrium between FSHR (rs6165) and
FSHR (rs6166), we decided to report the two polymorphisms separ-
ately for two reasons. Firstly, as stated above, the linkage disequilib-
rium between them is not universal (Simoni and Casarini, 2014).
Secondly, they seem to be associated with different COS outcomes.
For instance, Achrekar et al. (2009a) detected significant differences
in terms of total FSH consumption among FSHR (rs6165) genotypes
but not among FSHR (rs6166) genotypes. In addition, Trevisan et al.
(2014) observed that only the FSHR (rs6165) genotype influences the
number of embryos produced. Thus, these studies suggest that,
although in linkage disequilibrium, these two polymorphisms could
influence COS outcome in a different way.
The FSHR (rs1394205) polymorphism located in the 5′-untrans-
lated region of the gene has been extensively studied in association
with ovarian response. In Chinese hamster ovary cells, the transcrip-
tion activity of FSHR was significantly lower in A allele carriers than in
G allele carriers (Nakayama et al., 2006). In another study, even the
expression of FSHR was significantly lower in AA than in GG carriers
(Desai et al., 2011). Furthermore, the relative level of protein expres-
sion and membrane receptor expression in cumulus cells was signifi-
cantly lower in AA carriers than in carriers of other haplotypes
(Desai et al., 2011). Consequently, basic science evidence suggests
that the postulated role of FSHR (rs1394205) is more relevant in
modulating FSHR protein function versus FSHR (rs6166) and FSHR
(rs6165). At clinical level, we observed that FSHR (rs1394205) AA
carriers have a higher FSH consumption in COS than carriers of the
GG and AG haplotypes, and therefore, AA carriers may have an
impaired response to ovarian stimulation.
Limitations and strengths
Like all meta-analyses, our study has several limitations. First, most of
the studies included were observational and retrospective, and thus
more prone to bias. Second, the number of studies evaluating COS
outcomes in relation to the patient’s gonadotrophin receptor geno-
type is relatively small. Third, it was not possible to evaluate the
effect of alternate alleles on our findings because most trials did not
evaluate more than one SNP simultaneously. Fourth, the studies
included in our review were highly heterogeneous. This could be
probably explained by the wide variation in terms of populations and
treatment strategies. Lastly, OPRs were inconsistently reported in
the included studies, however, we were able to conduct a meta-
analysis for OPR with regard to the FSHR (rs6166), involving an
elevated number of observations (over 3000 patients). We used sev-
eral strategies to overcome these limitations. First, we applied
random-effect model to strengthen the validity of our results in case
of substantial heterogeneity among trials. Furthermore, we conducted
a sensitivity analysis in which we considered only papers with a low
risk of bias, namely those with a NOS score above 6. The observed
pooled effect sizes did not differ significantly from the overall analysis
except in a few cases. Hence, the consistency in the direction of our
findings is reliable and the methods were applied rigorously.
Future research
The pharmacogenomic approach to medical care is becoming a real-
ity in several fields, notably for patients at a high risk of adverse drug
reactions (Sychev and Malova, 2015). In the ART setting, a
pharmacogenomic approach to COS could lead to better standard-
ization of treatment, thereby increasing the chance of ART success
and reducing a potentially life-threatening excessive ovarian response.
Remarkably, no large randomized clinical trial on this topic has yet
been conducted notwithstanding the relatively high number of studies
published over the last 20 years. We believe that the pharmacoge-
nomic approach to COS is still a largely neglected topic in the repro-
ductive field. Furthermore, it noteworthy that most of the
polymorphisms reported in our review are widespread in the general
population and in women with reproductive disorders (Nilsson et al.,
1997; Alviggi et al., 2009, 2015; Simoni and Casarini, 2014), and that
genotype analysis can now be provided at the same costs of other
commonly used analyses (e.g. AMH, antral follicle count).
Conclusion
Our systematic review indicates that specific SNPs of the gonadotro-
phins and their receptors influence COS outcomes. This evidence is
supported by a large number of trials mainly devoted to FSHR (rs6165)
and FSHR (rs6166) polymorphisms. Our analysis shows that a higher
FSH consumption is expected in homozygotes for the A allele of the
FSHR (rs1394205) polymorphism than carriers of the G allele.
Moreover, FSHR (rs6166) GG homozygotes seem to be less respon-
sive to COS treatment. In fact, they have fewer oocytes than do AA
and AG carriers. It is feasible that the effect of these polymorphisms
on COS may partially explain the phenomenon of ‘hypo-response’ that
has been reported in 10–15% of normogonadotrophic ART women
(Alviggi et al., 2006; 2013). This peculiar ovarian response profile was
recently included in the new classification of low prognosis women
(Humaidan et al., 2016; Poseidon et al., 2016). Given the overall effect
of gonadotrophins and their receptor SNPs on COS, a pharmacoge-
nomic approach seems a promising strategy with which to improve the
clinical management of infertile women candidates for COS.
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Supplementary data are available at Human Reproduction Update online.
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